Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma-Reference-Cited by-同舟云学术

Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma

Published:2018-11-14 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Corre Sébastien,Tardif Nina,Mouchet Nicolas,Leclair Héloïse M.,Boussemart Lise,Gautron Arthur,Bachelot Laura,Perrot Anthony,Soshilov Anatoly,Rogiers Aljosja,Rambow Florian,Dumontet Erwan,Tarte Karin^ORCID,Bessede Alban,Guillemin Gilles J.^ORCID,Marine Jean-Christophe,Denison Michael S.,Gilot David^ORCID,Galibert Marie-Dominique^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-06951-2.pdf

Reference63 articles.

1. Davies, H. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).

2. Chapman, P. B. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

3. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085–3096 (2011).

4. Boussemart, L. et al. Secondary tumors arising in patients undergoing BRAF inhibitor therapy exhibit increased BRAF-CRAF heterodimerization. Cancer Res. 76, 1476–1485 (2016).

5. Corcoran, R. B., Settleman, J. & Engelman, J. A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2, 336–346 (2011).

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Aryl Hydrocarbon Receptor and Its Crosstalk: A Chemopreventive Target of Naturally Occurring and Modified Phytochemicals;Molecules;2024-09-10

2. Estimation of the Binding Affinities of Glycogen Phosphorylase Inhibitors by Molecular Docking to Support the Treatment of Type 2 Diabetes;PHYS CHEM RES;2024

3. Modulation of aryl hydrocarbon receptor activity by tyrosine kinase inhibitors (ponatinib and tofacitinib);Archives of Biochemistry and Biophysics;2024-09

4. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression;International Immunopharmacology;2024-08

5. Identification of aryl hydrocarbon receptor allosteric antagonists from clinically approved drugs;Drug Development Research;2024-07-11